The identification of the TP53 gene as a high-risk Cancer Predisposition Gene (CPG) in 1990, followed in rapid succession by the APC, BRCA1, BRCA2 and Lynch (formerly HNPCC) genes in 1991–1995, enabled the introduction of CPG testing into the cancer genetics clinic. Here, TP53 is linked to cancer.